Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials

Journal of Rheumatology

Volumn 33, Issue 4, 2006, Pages 722-731

  Chen, Junmin ^a,b   Liu, Chao ^a  

^a Australasian Cochrane Centre   (Australia)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Ankylosing spondylitis; Metaanalysis; Sulfasalazine

Indexed keywords

SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; ANOREXIA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; ENTHESITIS; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL ASSESSMENT; HUMAN; INSOMNIA; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RIGIDITY; SPINE DISEASE; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE; WELLBEING;

ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANGE OF MOTION, ARTICULAR; SPINE; SPONDYLITIS, ANKYLOSING; SULFASALAZINE; TREATMENT OUTCOME;

EID: 33645823692     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library. Issue 4. 2003. Chichester, UK: John Wiley & Sons, Ltd., 2003.
2. Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482-6.
3. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
4. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
5. Moreland LW, Russell AS, Paulus HE. Management of rheumatoid arthritis: the historical context. J Rheumatol 2001;28:1430-52.
6. Ransford RAJ, Langman MJS. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-39.
7. van der Heijde D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol 1999;246:945-7.
8. van der Heijde D, Braun J, McGonagle D, Siegel J. Treatment trials in ankylosing spondylitis: current and future considerations. Ann Rheum Dis 2002;61 Suppl III:iii24-iii32.
9. Corkill MM, Jobanputra P, Gibson T, Macfarlane DG. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: Failure to demonstrate a clinical effect. Br J Rheumatol 1990;29:41-5.
10. Davis MJ, Dawes PT, Beswick E, Lewin IV, Stanworth DR. Sulphasalazine therapy in ankylosing spondylitis: Its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol 1989;28:410-3.
11. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: A double blind controlled study in 60 patients. BMJ 1986;293:911-4.
12. Feltelius N, Hallgren R. Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 1986;45:396-9.
13. Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 1993;32:729-33.
14. Krajne I. Sulphasalazine in the treatment of ankylosing spondylitis [Serbocroatian]. Lijecnicki Vjesnik 1990;112:171-4.
15. Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988;31:1111-6.
16. Schmidt WA, Wierth S, Milleck D, Droste U, Gromnica-Ihle E. Sulphasalazine in ankylosing spondylitis: A prospective, randomized, double-blind, placebo-controlled study and comparison with other controlled studies [German]. Z Rheumatol 2002;61:159-67.
17. Taylor HG, Beswick EJ, Dawes PT. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 1991;10:43-8.
18. Winkler V. Sulphasalazine treatment in ankylosing spondylitis: A comparison of sulphasalazine with placebo. Magyar Reumatologia 1989;30 Suppl:29-37.
19. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1999;42:2325-9.
20. Dougados M, Boumier P, Amor B. Treatment of ankylosing spondylitis with salazosulfapyridine. A double-blind, controlled study in 60 patients [French]. Rev Rhum Mal Osteoartic 1987;54:255-60.
21. Dougados M, Nguyen M, Mijiyawa M, Amor B. Sulfasalazine in spondylarthropathies. Z Rheumatol 1990;49 Suppl 1:80.
22. Nissila M, Lahesmaa R, Leirisalo-Repo M, Lehtinen K, Toivanen P, Granfors K. Antibodies to Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis in ankylosing spondylitis: effect of sulfasalazine treatment. J Rheumatol 1994;21:2082-7.
23. Reda D, Anderson R, Abdellatif M, Williams D, Clegg D. Longitudinal analysis of binary data in the VA Cooperative Study of sulfasalazine for the treatment of seronegative spondyloarthropathies [abstract]. Control Clin Trials 1995;16 3 Supp 1:90s-91s.
24. Schmidt WA, Wierth S, Milleck D, Droste U, Gromnica-Ihle E. Sulphasalazine in ankylosing spondylitis: a prospective, randomized, double-blind, placebo-controlled study and meta-analysis of other controlled studies. Z Rheumatol 2000;59 Suppl 3:69.
25. Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, Hernandez-Garduno A, Goycochea-Robles MV. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002;61:941-2.
26. Burgos-Vargas R, Pacheco-Tena C, Vazquez-Mellado J. A short-term follow-up of enthesitis and arthritis in the active phase of juvenile onset spondyloarthropathies. Clin Exp Rheumatol 2002;20:727-31.
27. De Keyser F. A controlled, double-blind and randomized international multicenter study on sulphasalazine versus placebo in patients with spondylarthropathies [abstract]. Clin Exp Rheumatol 1995;13 Suppl 13:109.
28. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
29. Lehtinen A, Leirisalo-Repo M, Taavitsainen M. Persistence of enthesopathic changes in patients with spondylarthropathy during a 6-month follow-up. Clin Exp Rheumatol 1995;13:733-6.
30. Benitez-del-Castillo JM, Garcia-Sanchez J, Tradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000;14:340-3.
31. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
32. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNFa treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.